Abbonarsi

Diagnosis, prevention, and management of delirium in the intensive cardiac care unit - 23/01/21

Doi : 10.1016/j.ahj.2020.11.011 
Alejandro Cortés-Beringola, MD a, b, , Lourdes Vicent, MD, PhD a, , Roberto Martín-Asenjo, MD a, c, Elena Puerto, MD a, c, Laura Domínguez-Pérez, MD a, c, Ramón Maruri, MD a, c, Guillermo Moreno, RN, MSc a, c, d, María T. Vidán, MD, PhD d, e, f,  Fernando Arribas, MD, PhD a, c, d, Héctor Bueno, MD, PhD a, c, d, g,
a Intensive Cardiac Care Unit, Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain 
b Cardiology Department, Hospital Universitario Infanta Leonor, Madrid, Spain 
c CIBER de enfermedades CardioVasculares (CIBERCV), Madrid, Spain 
d Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain 
e Department of Geriatric Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain 
f CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain 
g Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain 

⁎⁎Reprint requsest: Héctor Bueno, M.D., PhD., FESC, FAHA, Intensive Cardiac Care Unit. Cardiology Department, Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.Intensive Cardiac Care Unit. Cardiology DepartmentHospital Universitario 12 de OctubreCentro Nacional de Investigaciones Cardiovasculares (CNIC)MadridSpain

Riassunto

Delirium is a frequent complication in patients admitted to intensive cardiac care units (ICCU) with potentially severe consequences including increased risks of mortality, cognitive impairment and dependence at discharge, and longer times on mechanical ventilation and hospital stay. Delirium has been widely documented and studied in general intensive care units and in patients after cardiac surgery, but it has barely been studied in acute nonsurgical cardiac patients. Moreover, delirium (especially in its hypoactive form) is commonly misdiagnosed. We propose a protocol for delirium prevention and management in ICCUs.

A daily comprehensive assessment to improve detection should be done using validated scales (ie, confusion assessment method). Preventive measures are particularly relevance and constitute the basis of treatment as well, acting on reversible risk factors, including environmental interventions, such as quiet time, sleep promotion, family support, communication, and adequate treatment of pain and dyspnea. Pharmacological prophylaxis is not indicated with the exception of patients at risk of withdrawal syndrome but should only be used in patients with confirmed delirium. Dexmedetomidine is the drug of choice in patients with severe agitation, and those weaning from invasive mechanical ventilation.

As the complexity of ICCUs increases, clinical scenarios posing challenges for the management of delirium become more frequent. Efforts should be done to improve the identification of patients at risk during admission in order to establish preventive interventions to avoid this complication. Patient-centered protocols will increase the awareness of the healthcare professionals for better prevention and earlier diagnosis and will positively impact on prognosis.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Funding: No extramural funding was used to support this work.
 Disclosures: Dr. Cortés-Beringola, Dr. Vicent, Dr. Martín-Asenjo, Dr. Puerto, Dr. Domínguez-Pérez, Dr. Maruri, Dr. Moreno, have nothing to disclose. Dr. Vidan has received financial support for attending scientific meetings and consulting fees from Novartis and speaking fees from Aula Fresenius. Dr. Arribas has received research funding from Daiichi Sankyo, Impulse Dynamics, Medtronic, Boston Scientific, Bayer, Bristol Meyers Squibb, Abbott, Novartis and research and educational payments to the Cardiology Department from Janssen Cylag, Biosensors and Edwards. Dr. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 & PI17/01799), Sociedad Española de Cardiología, Astra-Zeneca, Bayer, BMS and Novartis; has received consulting fees from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientific meetings from Amgen, Astra-Zeneca, Bayer, BMS-Pfizer, Novartis, and MEDSCAPE-the heart.org.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 232

P. 164-176 - febbraio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials
  • Husam M. Salah, Subhi J. Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J Paul Mounsey, Stephen J. Greene, Darren K. McGuire, Renato D. Lopes, Marat Fudim
| Articolo seguente Articolo seguente
  • Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program
  • Aaron E. Lottes, Eleni M. Whatley, Sara M. Royce, Daniel J. Bertges, Carla A. Erickson, Andrew Farb, Megan L. Fox, Jenny H. Jiang, Li Wang, Asiyah Y. Lin, Misti L. Malone, George Papandreou, Rebecca W. Wilgus, Kenneth Rosenfield, Mitchell W. Krucoff

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.